UPDATE: Raymond James On Sol-Gel Price Target Trim: Positive On Recent FDA Approval Of TWYNEO Which Prompted $3.5M Upfront Payment From Galderma; Believes Co. To Be 'Relatively Derisked With A Solid Risk/Reward Profile' With Consistent Cash Inflows

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!